The world lost 1.2 million people to drug-resistant infections in 2019, more than those lost to HIV or malaria. It is estimated that by 2050, as many as 10 million people could die annually due to drug-resistant infections. It will create a massive economic impact of $100 trillion. This highlights antimicrobial resistance (AMR) as a major public health concern. AMR occurs when bacteria escape antibiotics that are meant to kill them. AMR has been sped up over the last few decades due to the misuse and overuse of antibiotics, giving rise to superbugs—pathogens that are much harder to treat.
Despite the grim AMR scenario, the world’s consumption of antibiotics has been steadily increasing. A Lancet study reported a 46 percent increase in antibiotic consumption since 2000, with low and middle-income countries (LMICs) leading this surge. Increasing antibiotic consumption has resulted in an increasing AMR burden globally, particularly in LMICs where AMR-related deaths are at least four times higher than that in the developed world.
[This article has been reproduced with permission from the Indian School of Business, India]